BioStock: Alligator’s CEO: “We are not surprised by the positive readout”
Lund-based Alligator Bioscience continue to strengthen the case for their phase II candidate mitazalimab with 24-months data. BioStock reached out…
0,008€
Echtzeit-Aktienkurs Alligator Bioscience AB
Bid:
Ask:
Nachrichten zur Alligator Bioscience AB Aktie
BioStock: Updated data further bolsters Alligator’s mitazalimab
Lund-based Alligator Bioscience continue to strengthen the case for their phase II candidate mitazalimab. The stock jumped 67 per cent…
BioStock: Alligators CEO: "Im confident that we will strike a deal"
Alligator Bioscience is currently conducting a rights issue aimed at advancing mitazalimab towards phase III and securing a partnership. CEO…
BioStock: Alligator’s CEO: “We are on track to secure a partnership”
Alligator Bioscience is undertaking a restructuring and planning a rights issue of approximately SEK 280 million. This move aims to…
BioStock: Robust data drives Alligator Bioscience forward
Alligator Bioscience has certainly had a successful 2024 according to its Q3 report. With promising phase II results from its…
BioStock: Alligator brings in new CFO ahead of phase III
As Alligator Bioscience approaches phase III with its lead cancer immunotherapy candidate mitazalimab, increasing its business development activities has been…
BioStock: “Unprecedented” phase II data for Alligator in pancreatic cancer
Alligator Bioscience continues to post convincing phase II data with cancer immunotherapy mitazalimab in pancreatic cancer. Adding to the positive…
BioStock: Orion option exercise triggers milestone payment for Alligator
The collaboration between Alligator Bioscience and the global pharma company Orion Corporation continues to bear fruit. Orion has chosen to…
BioStock: Alligator Bioscience on the importance of prolonging life
What does time mean to a person whos cancer might not be cured? Prolonged life can bring hope for alternative…
BioStock: Alligator’s CEO on current development and the rights issue
The recent phase II success with mitazalimab means that Alligator Bioscience can now start preparing for phase III. Besides mitazalimab,…
BioStock: Clinical effects observed with Alligator’s 4-1BB agonist
Through its partnership with the US-based biotech Aptevo Therapeutics, Alligator Bioscience is evaluating the bispecific antibody ALG.APV-527 for the treatment…